PLoS ONE (Jan 2014)

High resolution melting analysis: a rapid screening and typing tool for common β-thalassemia mutation in Chinese population.

  • Min Lin,
  • Ji-Wei Jiao,
  • Xiu-Hui Zhan,
  • Xiao-Fen Zhan,
  • Mei-Chen Pan,
  • Jun-Li Wang,
  • Chun-Fang Wang,
  • Tian-Yu Zhong,
  • Qin Zhang,
  • Xia Yu,
  • Jiao-Ren Wu,
  • Hui-Tian Yang,
  • Fen Lin,
  • Xin Tong,
  • Hui Yang,
  • Guang-Cai Zha,
  • Qian Wang,
  • Lei Zheng,
  • Ying-Fang Wen,
  • Li-Ye Yang

DOI
https://doi.org/10.1371/journal.pone.0102243
Journal volume & issue
Vol. 9, no. 8
p. e102243

Abstract

Read online

β-thalassemia is a common inherited disorder worldwide including southern China, and at least 45 distinct β-thalassemia mutations have been identified in China. High-resolution melting (HRM) assay was recently introduced as a rapid, inexpensive and effective method for genotyping. However, there was no systemic study on the diagnostic capability of HRM to identify β-thalassemia. Here, we used an improved HRM method to screen and type 12 common β-thalassemia mutations in Chinese, and the rapidity and reliability of this method was investigated. The whole PCR and HRM procedure could be completed in 40 min. The heterozygous mutations and 4 kinds of homozygous mutations could be readily differentiated from the melting curve except c.-78A>G heterozygote and c.-79A>G heterozygote. The diagnostic reliability of this HRM assay was evaluated on 756 pre-typed genomic DNA samples and 50 cases of blood spots on filter paper, which were collected from seven high prevalent provinces in southern China. If c.-78A>G heterozygote and c.-79A>G heterozygote were classified into the same group (c.-78&79 A>G heterozygote), the HRM method was in complete concordance with the reference method (reverse dot blot/DNA-sequencing). In a conclusion, the HRM method appears to be an accurate and sensitive method for the rapid screening and identification of β-thalassemia mutations. In the future, we suggest this technology to be used in neonatal blood spot screening program. It could enlarge the coverage of β-thalassemia screening program in China. At the same time, its value should be confirmed in prospectively clinical and epidemiological studies.